Management of Primary Immune Thrombocytopenia: Turkish Modified Delphi-Based Consensus Statement for Special...

Area of Science:

• Hematology
• Immunology
• Internal Medicine

Background:

• Primary immune thrombocytopenia (ITP) is an acquired platelet disorder with complex, unclear mechanisms.
• Current ITP management guidelines need refinement for specific scenarios like pregnancy, emergencies, and co-medications.

Purpose of the Study:

• To determine Turkish hematologists' consensus on managing immune thrombocytopenia (ITP) in special circumstances.
• To establish practice guidance for ITP management during pregnancy, emergencies, and co-treatments.

Main Methods:

• Modified Delphi method employed by the Turkish National ITP Working Group.
• 107 hematologists surveyed via questionnaire on ITP management statements in two rounds.

Main Results:

• Agreement on initiating ITP treatment for pregnant patients with platelets <30x10^9/L.
• Delivery considered safe at platelet counts >50x10^9/L; emergency ITP management favors combination therapy over high-dose corticosteroids alone.
• Platelet counts >50x10^9/L deemed safe for low-risk procedures and co-treatment with antiplatelets/anticoagulants.

Conclusions:

• Need for enhanced practice guidance for primary ITP patients requiring interventions and co-treatments.
• ITP management during pregnancy requires individualized decisions.
• Lack of consensus on platelet count thresholds, comorbidities, and co-medications may stem from practice variations.